Congressional Research Service Reports - 53 Matching Results
Search Results
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report presents legislative changes affecting Pharmaceutical Patents related to the Hatch-Waxman Act.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Products Liability: A Legal Overview
- No Description Available.
- Consumer Bankruptcy and Household Debt
- Financial distress is most common among lower-income families, but its incidence has grown in all income brackets. This trend suggests that explanations for the rise in consumer bankruptcy filings are more likely to be found in micro-analysis of individuals and groups of debtors than in macroeconomic indicators. This report presents statistics on bankruptcy filings, household debt, and households in financial distress.
- Consumer Bankruptcy and Household Debt
- Financial distress is most common among lower-income families, but its incidence has grown in all income brackets. This trend suggests that explanations for the rise in consumer bankruptcy filings are more likely to be found in micro-analysis of individuals and groups of debtors than in macroeconomic indicators. This report presents statistics on bankruptcy filings, household debt, and households in financial distress.
- Consumer Bankruptcy and Household Debt
- Financial distress is most common among lower-income families, but its incidence has grown in all income brackets. This trend suggests that explanations for the rise in consumer bankruptcy filings are more likely to be found in micro-analysis of individuals and groups of debtors than in macroeconomic indicators. This report presents statistics on bankruptcy filings, household debt, and households in financial distress.
- Ecstasy: Legislative Proposals in the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Slamming: The Unauthorized Change of a Consumer's Telephone Service Provider
- No Description Available.
- Slamming: The Unauthorized Change of a Consumer's Telephone Service Provider
- No Description Available.
- Slamming: The Unauthorized Change of a Consumer's Telephone Service Provider
- No Description Available.
- Slamming: The Unauthorized Change of a Consumer's Telephone Service Provider
- No Description Available.
- Slamming: The Unauthorized Change of a Consumer's Telephone Service Provider
- No Description Available.
- Slamming: The Unauthorized Change of a Consumer's Telephone Service Provider
- No Description Available.
- Telemarketing: Dealing with Unwanted Telemarketing Calls
- This report provides summaries of the federal laws and regulations particular to telemarketing, the establishment of a national do-not-call registry, and the options that are available to consumers to limit the calls that they receive from telemarketers and to report questionable telemarketing practices to local or federal authorities. The report also lists sources of additional information with addresses, phone numbers, and Internet sites (if available).
- Telemarketing: Dealing with Unwanted Telemarketing Calls
- This report provides summaries of the federal laws and regulations particular to telemarketing, the establishment of a national do-not-call registry, and the options that are available to consumers to limit the calls that they receive from telemarketers and to report questionable telemarketing practices to local or federal authorities. The report also lists sources of additional information with addresses, phone numbers, and Internet sites (if available).
- Telemarketing: Dealing with Unwanted Telemarketing Calls
- This report provides summaries of the federal laws and regulations particular to telemarketing, the establishment of a national do-not-call registry, and the options that are available to consumers to limit the calls that they receive from telemarketers and to report questionable telemarketing practices to local or federal authorities. The report also lists sources of additional information with addresses, phone numbers, and Internet sites (if available).
- Telemarketing: Dealing with Unwanted Telemarketing Calls
- This report provides summaries of the federal laws and regulations particular to telemarketing, the establishment of a national do-not-call registry, and the options that are available to consumers to limit the calls that they receive from telemarketers and to report questionable telemarketing practices to local or federal authorities. The report also lists sources of additional information with addresses, phone numbers, and Internet sites (if available).
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- Fair Credit Reporting Act: Frequently Asked Questions
- As financial privacy issues are debated in Congress, numerous questions about the Fair Credit Reporting Act (FCRA) have emerged. Enacted in 1970, the Fair Credit Reporting Act is the federal statute that establishes a regulatory framework for credit reporting in the United States and establishes a consumer’s rights with respect to his or her credit report. This report attempts to answer frequently asked questions about the Fair Credit Reporting Act.
- Fair Credit Reporting Act: Frequently Asked Questions
- As financial privacy issues are debated in Congress, numerous questions about the Fair Credit Reporting Act (FCRA) have emerged. Enacted in 1970, the Fair Credit Reporting Act is the federal statute that establishes a regulatory framework for credit reporting in the United States and establishes a consumer’s rights with respect to his or her credit report. This report attempts to answer frequently asked questions about the Fair Credit Reporting Act.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- Class Actions and Proposed Reform in the 108th Congress: Class Action Fairness Act of 2003
- The report discusses the consumer class action bill of rights in each proposal contains safeguards which provide for judicial scrutiny of coupon and other non-cash settlements, protection against a proposed settlement that would result in a net loss to a class member, protection against discrimination based upon geographic location, and prohibition on a class representative receiving a greater share of the award.
- Medicare: Beneficiary Cost-Sharing Under Prescription Drug Legislation
- This report provides an analysis of how the cost-sharing and premium provisions under the Prescription Drug and Medicare Improvement Act of 2003 (S. 1) and the Medicare Prescription Drug and Modernization Act of 2003 (H bill would affect the amount that a beneficiary would pay annually for prescription drugs.
- Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
- This report examines these proposals as well as the “Medicare Rx Drug Benefit and Discount Act of 2003,” which was introduced by Representative Charles Rangel, the ranking member of the House Ways and Means Committee. Specifically, this report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs.
- President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
- No Description Available.
- Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
- This report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs. In addition, this report gives examples of how annual cost-sharing would differ for beneficiaries with various levels of total prescription drug spending in 2006 under the plans.
- Protection of Lawful Commerce in Arms Act, H.R. 1036, S. 659, S. 1805, S. 1806, 108th Congress: Legal Analysis
- No Description Available.
- Protection of Lawful Commerce in Arms Act, H.R. 1036 and S. 659, 108th Congress: Legal Analysis
- No Description Available.
- Protection of Lawful Commerce in Arms Act, H.R. 1036, 108th Congress: Legal Analysis
- No Description Available.
- Geographical Indications and WTO Negotiations
- This report discusses the issue of expanding intellectual property protections for geographical indications for wines, spirits, and agricultural products is being debated in the World Trade Organization (WTO).
- Copyright Law: Digital Rights Management Legislation
- Digital Rights Management (DRM) refers to the technology that copyright owners use to protect digital media. This report surveys several of the DRM bills that were introduced in the 107th Congress and those that are pending in the 108th Congress. Generally, the bills are directed at two separate goals. One goal is to increase access to digitally-protected media for lawful purposes. The other attempts to thwart digital piracy and would do so by enhancing civil and criminal sanctions for digital copyright infringement and educating the public about the rights of copyright holders.
- Identity Theft and the Fair Credit Reporting Act: An Analysis of
- This report provides information about An Analysis of on Identity Theft and the Fair Credit Reporting Act. This report will provide a brief summary of the fair credit reporting act provisions in question, as well as an analysis of the recent supreme court decisions.
- Medicare Prescription Drug and Reform Legislation
- This report describes the major features of S. 1, as ordered reported, and the measure to be considered by the House Ways and Means Committee, H.R. 2473, as ordered reported.
- Overview of the Medicare Prescription Drug and Reform Legislation
- No Description Available.
- Medicare Prescription Drug Provisions of S.1, as Passed by the Senate, and H.R. 1, as Passed by the House
- This report discusses differences in the specifics of the prescription drug provisions in S. 1 and H.R. 1 and provides a side-by-side comparison of the Title I provisions of both bills.
- Identity Theft and the Fair Credit Reporting Act: An Analysis of
- This report provides information about An Analysis of on Identity Theft and the Fair Credit Reporting Act. This report will provide a brief summary of the fair credit reporting act provisions in question, as well as an analysis of the recent supreme court decisions.
- Identity Theft and the Fair Credit Reporting Act: An Analysis of
- This report provides information about An Analysis of on Identity Theft and the Fair Credit Reporting Act. This report will provide a brief summary of the fair credit reporting act provisions in question, as well as an analysis of the recent supreme court decisions.